RecruitingNCT05839379

Targeted Pediatric High-Grade Glioma Therapy

Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma

Sponsor

Nationwide Children's Hospital

Enrollment

350 participants

Start Date

Aug 2, 2024

Study Type

OBSERVATIONAL

Conditions

Metastatic Brain Tumor Glioblastoma Glioblastoma Multiforme High Grade Glioma Diffuse Intrinsic Pontine Glioma Anaplastic Astrocytoma WHO Grade III Glioma WHO Grade IV Glioma Diffuse Midline Glioma, H3 K27M-Mutant

Summary

The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.

Eligibility

Min Age: 12 MonthsMax Age: 39 Years

Plain Language Summary

Simplified for easier understanding

This study screens children and young adults with newly diagnosed high-grade brain tumors — including DIPG (diffuse intrinsic pontine glioma, an aggressive tumor in the brainstem) — to identify specific genetic mutations. The goal is to match patients to targeted treatments based on their tumor's molecular profile. **You may be eligible if...** - You are between 12 months and 39 years old - You have a newly diagnosed high-grade brain tumor (including DIPG) confirmed by biopsy or surgery - The diagnosis has been reviewed and confirmed by a pathologist **You may NOT be eligible if...** - Your tumor has not been confirmed by tissue biopsy - You have a low-grade brain tumor - You have already received treatment for this brain tumor without the required tumor profiling Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(21)

Children's Hospital Colorado

Aurora, Colorado, United States

Children's National Medical Center

Washington D.C., District of Columbia, United States

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

C.S. Mott Children's Hospital

Ann Arbor, Michigan, United States

Duke University Health System

Durham, North Carolina, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Nationwide Children's Hospital

Columbus, Ohio, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Texas Children's Hospital

Houston, Texas, United States

Seattle Children's Hospital

Seattle, Washington, United States

Sydney Children's Hospital

Randwick, New South Wales, Australia

Queensland Children's Hospital

South Brisbane, Queensland, Australia

Royal Children's Hospital

Melbourne, Victoria, Australia

Perth Children's Hospital

Perth, Western Australia, Australia

The Hospital for Sick Children (SickKids)

Toronto, Ontario, Canada

Montreal Children's Hospital

Montreal, Quebec, Canada

Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)

Heidelberg, Baden-Wurttemberg, Germany

Princess Máxima Center

Utrecht, Netherlands

Starship Children's Hospital

Auckland, Grafton, New Zealand

Great Ormond Street Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05839379

Related Trials

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

NCT053034679 locations

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

NCT071955914 locations

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT0655656393 locations

Sonodynamic Therapy in Patients With Recurrent GBM

NCT060397091 location